Neutropenia management

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Schouten, H C ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CORTICOSTEROID; CYTOTOXIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ABSENCE OF SIDE EFFECTS; ANTIBIOTIC PROPHYLAXIS; ARTICLE; B LYMPHOCYTE; BACTERIAL INFECTION; CANCER THERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE CLASSIFICATION; FEBRILE NEUTROPENIA; GRANULOCYTE; HOST RESISTANCE; HUMAN; INFECTION; INFECTION RESISTANCE; INFLAMMATION; MACROPHAGE; MONOCYTE; MYCOSIS; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

HUMANS; NEUTROPENIA;

EID: 33749630748     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl243     Document Type: Article

References (43)

1. O'Brien SN, Blijlevens NMA, Mahfouz TH, Anaissie EJ. Infections in Patients with Hematological Cancer: Recent Developments. Hematology 2003; 2003: 438.
2. Boggs DR. The kinetics of neutrophilic leukocytes in health and in disease. Seminars of Hematology 1967; 4: 359-386.
3. Dale DC, Liles WC. Neutrophils and Monocytes: Normal physiology and disorders of neutrophil and monocyte production. In Handin RI, Lux SE, Stossel TP (eds): Blood; Principles and Practise of Hematology, Edition second. Philadelphia: Lippincot Williams & Wilkins 2003; 455-482.
4. Palmblad J, van der Klauw MM, Stricker BHC. Drug-Induced Neutropenias: Now and Then. Arch Intern Med 1999; 159: 2745.
5. van der Klauw MM, Goudsmit R, Halie MR et al. A Population-Based Case-Cohort Study of Drug-Associated Agranulocytosis. Arch Intern Med 1999; 159: 369-374.
6. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
7. Lalami Y, Paesmans M, Muanza F et al. Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. Ann Oncol 2006; 17 (3): 507-514.
8. Rubin M, Hathorn JW, Pizzo PA. Controversies in the management of febrile neutropenic cancer patients. Cancer Invest 1988; 6: 167-184.
9. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988; 148: 2561-2568.
10. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10: 316-322.
11. Pizzo PA, Robichaud KJ, Wesley R, Commers JR. Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine (Baltimore) 1982; 61: 153-165.
12. Bucaneve G, Micozzi A, Menichetti F et al. Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia.,N Engl J Med 2005; 353: 977-987.
13. Oude Nijhuis C, Kamps WA, Daenen SMG et al. Feasibility of Withholding Antibiotics in Selected Febrile Neutropenic Cancer Patients. J Clin Oncol 2005; 23: 7437-7444.
14. Innes HE, Smith DB, O'Reilly SM et al. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: A prospective randomised controlled single centre study. Br J Cancer 2003; 89: 43-49.
15. Love LJ, Schimpff SC, Schiffer CA, Wiernik PH: Improved prognosis for granulocytopenic patients with gram-negative bacteremia. Am J Med 1980; 68: 643-648.
16. Viscoli C, Vamier O, Machetti M. Infections in patents with febrile neutropenia: Epidemiology, microbiology, and risk stratification. Clin Infect Dis 2005; 40 Suppl 4: S240-245.
17. Viscoli, Castagnola. Planned progressive antimicrobial therapy in neutropenic patients. British Journal of Haematology 1998; 102: 879-888.
18. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36: 1103-1110.
19. Yadegarynia D, Tarrand J, Read I, Rolston K. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis 2003; 37: 1144-1145.
20. Greil R, Jost LM. ESMO recommendations for the application of hematopoietic growth factors. Ann Oncol 2005; 16: 180-82.
21. Castagnola E, Paola D, Giacchino R, Viscoli C. Clinical and laboratory features predicting a favorable outcome and allowing early discharge in cancer patients with low-risk febrile neutropenia: A literature review. J Hematother Stem Cell Res 2000; 9: 645-649.
22. Klastersky J, Paesmans M, Rubenstein EB et al. The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients. J Clin Oncol 2000; 18: 3038-3051.
23. Donnelly JP. Selective decontamination of the digestive tract and its role in antimicrobial prophylaxis. J Antimicrob Chemother 1993; 31: 813-829.
24. Lew MA, Kehoe K, Ritz J et al. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation 1991; 51: 630-636.
25. Phillips KA, Tannock IF. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol 1998; 16: 3179-3190.
26. Bokemeyer C, Kuczyk MA, Kohne H et al. Hematopoietic growth factors and treatment of testicular cancer: Biological interactions, routine use and dose-intensive chemotherapy. Ann Hematol 1996; 72: 1-9.
27. Fossa SD, Kaye SB, Mead GM et al. Filgrastim during combination chemotherapy of patients with poor- prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998; 16: 716-724.
28. Ozer H, Armitage JO, Bennett CL et al. Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. J Clin Oncoll 2000; 18: 3558-3585.
29. Gomez H, Hidalgo M, Casanova L et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. Journal of Clinical Oncology 1998; 16: 2065.
30. Tjan-Heljnen VC, Postmus PE, Ardizzoni A et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study. Ann Oncol 2001; 12: 1359-1368.
31. Timmer-Bonte JN, de Boo TM, Smit HJ et al. Prevention of Chemotherapy-Induced Febrile Neutropenia by Prophylactic Antibiotics Plus or Minus Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer: A Dutch Randomized Phase III Study. J Clin Oncol 2005; 23: 7974-7984.
32. Lowenberg B, Boogaerts MA, Daenen SM et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997; 15: 3496.
33. Cullen M, Steven N, Billingham L et al. Antibacterial Prophytaxis after Chemotherapy for Solid Tumors and Lymphomas. N Engl J Med 2005; 353: 988-998.
34. Escalante CP, Weiser MA, Manzullo E et al. Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Supportive Care in Cancer 2004; 12: 657-662.
35. Vidal L, Paul M, Ben dor I et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: A systematic review and meta-analysis of randomized trials. J. Antimicrob. Chemother. 2004; 54: 29-37.
36. Frelfeld A, Marchigiani D, Walsh T et al, A Double-Blind Comparison of Empirical Oral and Intravenous Antibiotic Therapy for Low-Risk Febrile Patients with Neutropenia during Cancer Chemotherapy. N Engl J Med 1999; 341: 305-311.
37. Pizzo PA. Management of fever in patents with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323-1332.
38. Clark OAC, Lyman GH, Castro AA et al. Colony-Stimulating Factors for Chemotherapy-Induced Febrile Neutropenia: A Meta-Analysis of Randomized Controlled Trials. J Clin Oncol 2005; 23: 4198-4214.
39. Vellenga E, Uyl-de Groot CA, de Wit R et al. Randomized placebo-controlled trial of granulocyte-macrophage colony- stimulating factor in patents with chemotherapy-related febrile neutropenia. J Clin Oncol 1996; 14: 619-627.
40. Garcia-Carbonero R, Mayordomo JI, Tornamira MV et al. Granulocyte Colony-Stimulating Factor in the Treatment of High-Risk Febrile Neutropenia: A Multicenter Randomized Trial, J Natl Cancer Inst 2001; 93: 31-38.
41. Green MD, Koelbl H, Baselga J et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy, Ann Oncol 2003; 14: 29-35.
42. Holmes FA, O'Shaughnessy JA, Vukelja S et al, Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer. J Clin Oncol 2002; 20: 727-731.
43. Timmer-Bonte JNH, Mulder PHM, Peer PGM et al. Timely Withdrawal of G-CSF Reduces the Occurrence of Thrombocytopenia During Dose-dense Chemotherapy. Breast Cancer Res Treat 2005; 93: 117-123.